Why the study?
Heart failure and sudden cardiac death increase with CKD progression largely due to CKD-associated cardiomyopathy, which is driven by hypertension and presents even in mild to moderate renal impairment.
Design
Review
Key result
Hypertension is a primary driver in the pathogenesis of chronic kidney disease-associated cardiomyopathy, which is characterized by left ventricular hypertrophy, dysfunction, and myocardial fibrosis.
Authors
Loading...
Supports prioritizing hypertension control in CKD cardiomyopathy; leaves open optimal strategies for fibrosis and dysfunction.
This review summarizes the epidemiology, pathogenesis, and treatment of CKD-associated cardiomyopathy, emphasizing the central role of hypertension.
Law et al. (2022) conducted a review in Chronic kidney disease-associated cardiomyopathy and hypertension. Hypertension is a primary driver in the pathogenesis of chronic kidney disease-associated cardiomyopathy, which is characterized by left ventricular hypertrophy, dysfunction, and myocardial fibrosis.